Urology News and Research

Latest Urology News and Research

PSA test benefits are questionable, yet physicians struggle to stop them

Recent recommendations from the U.S. Preventive Services Task Force (USPSTF) advising elimination of routine prostate-specific antigen (PSA) screening for prostate cancer in healthy men are likely to encounter serious pushback from primary care physicians, according to results of a survey by Johns Hopkins investigators.

24 May 2012

NYU Langone surgeons perform robotic-assisted partial nephrectomy in New York

A team of urological surgeons from NYU Langone Medical Center performed a robotic-assisted partial nephrectomy in New York and beamed the procedure from New York via high definition satellite to more than 400 participants attending the American Urological Association's (AUA) 2012 Annual Meeting in Atlanta earlier this week.

24 May 2012

Number of Americans with kidney stones nearly doubled since 1994

The number of Americans suffering from kidney stones between 2007 and 2010 nearly doubled since 1994, according to a study by researchers at the University of California, Los Angeles (UCLA) and RAND.

24 May 2012

CMS sticks with Medicare coverage of PSA test

The federal government is not changing coverage plans "at this time." Meanwhile, a number of urologists and other medical specialists raise concerns that new recommendations against prostate cancer screening will hurt men's health.

24 May 2012

RARP more costly than RRP in treating prostate cancer

In one of the most comprehensive analyses to date of the cost of robotic-assisted, laparoscopic surgery for prostate cancer, researchers at UPMC found that this now-dominant surgical approach is significantly more costly than standard open surgery, despite little scientific evidence of long-term improved patient outcomes.

24 May 2012

Study shows how chromosomal mutation likely contributes to early development of prostate cancer

Up to half of all prostate cancer cells have a chromosomal rearrangement that results in a new "fusion" gene and formation of its unique protein -- but no one has known how that alteration promotes cancer growth. Now, Weill Cornell Medical College researchers have found that in these cancer cells, the 3-D architecture of DNA, wrapped up in a little ball known as a chromatin, is warped in such a way that a switch has been thrown on thousands of genes, turning them on or off to promote abnormal, unchecked growth. Researchers also found that new chromosomal translocations form, further destabilizing the genome.

23 May 2012

MDxHealth announces availability of ConfirmMDx for Prostate Cancer test

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced it has presented data demonstrating that its epigenetic ConfirmMDx for Prostate Cancer test can aid urologists in identifying patients who may avoid a repeat prostate biopsy.

23 May 2012

Cooper Green installs Medsphere's OpenVista EHR

MedsphereSystems Corporation and Cooper Green Mercy Hospital today announced that Cooper Green has gone live on Medsphere's OpenVista open source electronic health record (EHR).

22 May 2012

AUA includes percutaneous tibial nerve stimulation in OAB treatment guidelines

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that the American Urological Association (AUA) issued a clinical guideline titled "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults," which includes percutaneous tibial nerve stimulation (PTNS) as an integral part of the care path for overactive bladder (OAB) treatment.

22 May 2012

LUGPA discredits recommendations by USPSTF to stop prostate cancer testing

The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today discredited recommendations by the U.S. Preventive Services Task Force (USPSTF) to stop prostate cancer testing.

22 May 2012

Combination of vitamin D and BCG vaccine improves bladder cancer survival

The tuberculosis vaccine is often used as a treatment for bladder cancer, and adding vitamin D might improve the vaccine's effectiveness, according to new research from the University of Rochester Medical Center presented today at the American Urological Association annual meeting.

22 May 2012

AltheRx reports positive Phase II results of Solabegron for OAB

AltheRx Pharmaceuticals, a privately-held clinical development company, presented positive results from its Phase II study of Solabegron in overactive bladder (OAB) at the American Urological Association Annual Meeting (Abstract # 520).

21 May 2012

Treatment of early stage prostate cancer can also result in improved QOL for men with LUTS

Treatment of early stage prostate cancer can also result in improved quality of life for a subgroup of men who suffer from lower urinary tract symptoms (LUTS), according to an abstract of a Beth Israel Deaconess Medical Center-led study presented to the American Urological Association.

21 May 2012

Study uncovers distinct subtype of prostate cancer

A collaborative expedition into the deep genetics of prostate cancer has uncovered a distinct subtype of the disease, one that appears to account for up to 15 percent of all cases, say researchers at Weill Cornell Medical College, the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute.

21 May 2012

Urologic conditions contribute to major economic burden in the U.S.

Urologic conditions like urinary tract infections, kidney stones, and prostate cancer are a major economic burden on Americans, resulting in health care costs of close to $40 billion annually, according to a newly released national report that charts the demographic and economic impact of urologic diseases in the U.S.

19 May 2012

Patients with muscle-invasive bladder cancer benefit from accelerated MVAC

For some patients with muscle-invasive bladder cancer, treatment may begin before they undergo cystectomy, or surgical removal of the bladder. They may be advised by oncologists to receive chemotherapy before surgery. A large randomized clinical trial published in 2003 demonstrated a survival benefit for neoadjuvant, or pre-surgical, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) using a standard dose and schedule.

18 May 2012

TJU researchers to investigate Cu-64 imaging agent for prostate cancer

Jefferson's Kimmel Cancer Center and the Department of Radiology at Thomas Jefferson University received a five-year, $2.6 million grant from the National Institutes of Health (NIH) to investigate a potentially revolutionary method that can stage prostate cancers and detect recurrent disease so accurately, it would significantly reduce the number of confirmation biopsies. Such biopsies can be invasive, costly, and often lead to false-positive readings.

17 May 2012

Treatment in hospitals with medical fellowships improves outcome for prostate cancer radical surgery

Patients who undergo radical surgery for prostate cancer may expect better results, on average, if they're treated in accredited teaching hospitals with residency programs, and better still if the hospitals also have medical fellowships, according to a new study by Henry Ford Hospital.

16 May 2012

Racial disparities found in results of surgery to remove diseased prostates

Black prostate cancer patients may not be getting the same quality of care as white patients, according to a first-of-its-kind study by researchers at Henry Ford Hospital who found racial disparities in the results of surgery to remove diseased prostates.

16 May 2012

Older, high-risk prostate cancer patients get better results in larger hospitals

Older, sicker, high-risk patients who undergo one of the most common treatments for prostate cancer get better results in larger, busier hospitals, according to new research by Henry Ford Hospital.

16 May 2012